Australia markets closed
  • ALL ORDS

    7,577.20
    +18.40 (+0.24%)
     
  • AUD/USD

    0.7712
    +0.0002 (+0.02%)
     
  • ASX 200

    7,312.30
    +9.80 (+0.13%)
     
  • OIL

    70.95
    +0.04 (+0.06%)
     
  • GOLD

    1,877.40
    -2.20 (-0.12%)
     
  • BTC-AUD

    50,513.69
    +3,721.60 (+7.95%)
     
  • CMC Crypto 200

    924.19
    -17.62 (-1.87%)
     

Adverum Stockholders Re-Elect All Adverum Director Nominees at 2021 Annual Meeting

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
  • Oops!
    Something went wrong.
    Please try again later.

REDWOOD CITY, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that, based on a preliminary vote count provided by its proxy solicitors following its 2021 Annual Meeting of Stockholders, stockholders have voted to re-elect all three of Adverum’s highly qualified director nominees – Dawn Svoronos, Reed V. Tuckson, M.D. and Thomas Woiwode, Ph.D. – to the Adverum Board of Directors, ratified the selection of Ernst & Young LLP as independent auditors and approved, on an advisory basis, the compensation of Adverum’s named executive officers.

Adverum issued the following statement:

The Adverum Board and management team appreciate the support of our stockholders and the constructive feedback we received throughout this process. We are encouraged that stockholders recognize the strength of our Board, management team and strategy to drive Adverum forward. Adverum is laser focused on conducting a thorough review of data from the ADVM-022 program, and patient safety remains its top priority.

The results of the vote announced today are considered preliminary until final results are tabulated and certified by the independent Inspector of Elections. Final results will be reported on a Form 8-K that will be filed with the U.S. Securities and Exchange Commission.

About Adverum Biotechnologies

Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. For more information, please visit www.adverum.com.

Investor Relations Contact

Myesha Lacy
Vice President, Investor Relations and Corporate Communications
Adverum Biotechnologies, Inc.
T: 650-649-1257
E: mlacy@adverum.com

Or

Scott Winter / Gabrielle Wolf
Innisfree M&A Incorporated
T: 212-750-5833

Media Contact

Andrea Cohen
Sam Brown Inc.
T: 917-209-7163
E: andreacohen@sambrown.com

Or

Dan Moore
Joele Frank, Wilkinson Brimmer Katcher
T: 212-355-4449